NervGen Pharma Nears Completion of NVG-291 Spinal Cord Injury Trial Enrollment and Data Release

NervGen Pharma Corp., a biotech firm focused on nervous system repair, is nearing the completion of participant recruitment for its Phase 1b/2a clinical trial of NVG-291, a potential spinal cord injury treatment. The company anticipates releasing data from the chronic cohort in the third quarter of 2024. NVG-291 has shown promise in preclinical studies for both acute and chronic spinal cord injuries. The trial, which is taking place at the Shirley Ryan AbilityLab in Chicago, a renowned center for severe and complex medical conditions, is designed to assess the drug's efficacy using a variety of measures, including clinical outcomes and electrophysiological assessments.
NervGen is also planning a subsequent study where participants who were initially given a placebo will have the opportunity to receive NVG-291 under an open-label protocol, pending positive efficacy signals and regulatory approvals. The company's Chief Medical Officer, Dan Mikol, expressed optimism about the study's progress and the potential for NVG-291 to become the first approved treatment for spinal cord injuries.
The Shirley Ryan AbilityLab team, led by Monica A. Perez, is enthusiastic about the ongoing trial and the innovative design incorporating electrophysiology. The trial is partially funded by a grant from Wings for Life, an organization supporting the translation of scientific discoveries into therapeutic applications.
NVG-291 is a novel therapeutic peptide derived from the receptor protein tyrosine phosphatase sigma (PTPσ) and has received Fast Track Designation from the FDA. NervGen is committed to developing treatments that promote self-repair of the nervous system following injury or disease, with spinal cord injury as its primary focus. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!